TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Amneal Pharmaceuticals, Inc. (NYSE:NASDAQ:AMRX) recently reported that its Executive Vice President and Chief Financial Officer, Tasos Konidaris, sold a significant portion of his holdings in the company. According to the SEC filing, Konidaris sold 100,000 shares of Class A Common Stock on March 5, 2025. The sale comes as the stock trades near its 52-week high of $9.47, having delivered an impressive 65% return over the past year. InvestingPro analysis suggests the stock is currently fairly valued, with analysts setting price targets between $11-12. The shares were sold at an average price of $8.91, generating a total transaction value of approximately $891,000.
The sale was executed at prices ranging from $8.84 to $8.98 per share. Following this transaction, Konidaris retains ownership of 621,882 shares. This move comes in the midst of an active period for Amneal Pharmaceuticals, as the company continues to navigate the competitive pharmaceutical landscape.
In other recent news, Amneal Pharmaceuticals reported its Q4 2024 financial results, revealing a slight shortfall in earnings per share (EPS) but exceeding revenue expectations. The company announced an EPS of $0.12, which was below the anticipated $0.15, while revenue reached $731 million, surpassing the forecasted $703.74 million. Amneal also revealed a significant annual revenue of $2.8 billion for 2024, marking a 17% increase from the previous year. In collaboration with mAbxience, Amneal has had its Biologics Licensing Application accepted by the FDA for two biosimilars of denosumab, with a target action date set for the fourth quarter of 2025. These biosimilars are intended as alternatives to Prolia® and XGEVA®, which have generated significant sales in the U.S. Amneal recently launched a new Parkinson’s drug, Krexant, with promising sales targets and has set a revenue guidance range of $3.0 to $3.1 billion for 2025. The company is also focused on expanding its biosimilars portfolio, with plans to launch additional biosimilars by 2027. Additionally, Amneal has been working on reducing its net leverage and has received credit upgrades from S&P and Moody’s, reflecting its improved financial profile.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.